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ABStRACt Many studies have suggested that cardiovascular risk factors 
seem to be more common in patients with psoriasis than in the general 
population. In this study we aimed to determine the prevalence of cardio-
vascular risk factors in patients with chronic plaque psoriasis depending on 
the severity of disease. We conducted a prospective study in Braşov County 
(Romania) including 142 patients with chronic plaque psoriasis and dis-
ease duration of at least six months and 167 controls without psoriasis. 
The severity of psoriasis was assessed using the psoriasis area and sever-
ity index (PASI) score. Along with a thorough medical history and physical 
examination, serum lipid profile and fasting plasma glucose tests were car-
ried out. The 10-year Framingham risk score (FRS) for general cardiovascu-
lar disease, which includes age, gender, total cholesterol, HDL-cholesterol, 
systolic blood pressure, smoking status, and diabetes mellitus, was applied. 
The severity of chronic plaque psoriasis was mild in 32 patients (22.53%) 
and moderate to severe in 110 patients (77.47%). We found a significant 
higher prevalence of metabolic syndrome in the patient group compared 
to controls. Individual components of metabolic syndrome like waist cir-
cumference, elevated triglycerides, reduced HDL-C, impaired fasting plas-
ma glucose, and arterial hypertension were also more prevalent in patients 
than in controls. Mean triglycerides, total cholesterol, LDL-cholesterol and 
HDL-cholesterol levels were significantly raised in patients with psoriasis 
when compared to controls. The 10-year FRS was significantly higher in pa-
tients with psoriasis than in controls (8.36±5.75 vs. 6.61±4.13; P<0.001). FRS 
was higher in men (P=0.012) and in patients older than 50 years (P=0.008). 
According to the severity of psoriasis, FRS increases significantly from mild 
to moderate-to-severe psoriasis (6.82±4.48 to 8.8±6.71; P=0.003). Psoria-
sis, and especially moderate to severe psoriasis, seems to represent a risk 
factor for cardiovascular disease. Patients with psoriasis should be risk-as-
sessed for cardiovascular diseases, and comorbidities should be actively 
managed.




Psoriasis is one of the most common dermatologi-
cal diseases, with a prevalence of about 1-3% in the 
general population (1). In addition to the skin mani-
festations that affects the physical, social, and psycho-
logical aspects of the life of patients with psoriasis, 
other systemic diseases can also constantly occur in 
these patients. Comorbidities classically associated 
with psoriasis are arthritis, digestive inflammatory 
diseases (Crohn’s disease, ulcerative colitis), and de-
pressive psychiatric disorders. In recent years, the list 
of co-morbidities has expanded to include arterial hy-
pertension (AH), obesity, metabolic syndrome (MS), 
diabetes mellitus (DM), and dyslipidemia, which are 
known as traditional risk factors for cardiovascular dis-
ease (2-5); but psoriasis itself and the systemic treat-
ment of psoriasis may also stimulate premature ath-
erogenesis, increasing the cardiovascular risk (6). We 
conducted a prospective observational case-control 
study to determine the prevalence of cardiovascular 
risk factors in patients with chronic plaque psoriasis. 
PAtIentS And MethodS 
Between June 2012 and December 2013, 142 pa-
tients with chronic plaque psoriasis aged between 18 
and 82 years, 75 men and 67 women, with a mean 
age of 49.51±18.26 years and M/F ratio of 1.12 were 
included in study. Additionally, 167 patients with 
similar age and gender characteristics as the study 
group (aged between 18 and 79 years; mean age of 
47.87±16.43 years, 88 men and 79 women; sex ratio 
M/F=1.11) were included in the control group con-
sisting of patients without psoriasis. Patients in both 
groups were recruited from in- or out-patients from 
the Dermatology Department of the County Emer-
gency Hospital of Brasov, Romania. For assessment of 
cardiovascular risk factors according to age, patients 
of both groups were divided into two categories: un-
der and over 50 years. All the patients with psoriasis 
underwent clinical and histopathological diagno-
sis for chronic plaque type psoriasis. The severity of 
psoriasis was assessed using the psoriasis area and 
severity index (PASI) score. Psoriasis was considered 
mild if the PASI score was lower than 10, and moder-
ate-to-severe if PASI was over 10 (7). Data about age 
at psoriasis onset and previous therapy were also col-
lected. 
Exclusion criteria were history of renal or liver fail-
ure, hypothyroidism, and systemic therapy for pso-
riasis or treatment with lipid lowering drugs in the 3 
months prior to enrollment in order to eliminate fac-
tors influencing the serum lipids levels.
Laboratory investigations along with a thorough 
medical history and physical examination were car-
ried out to diagnose comorbidities. Blood sampling 
was performed after an overnight fast to determine 
serum triglycerides, total cholesterol (TC), high den-
sity lipoprotein-cholesterol (HDL-C), low density li-
poprotein-cholesterol (LDL-C), and fasting plasma 
glucose (FPG). Oral glucose tolerance test (OGTT) 
and determination of glycated hemoglobin A1c were 
also performed in cases of abnormal levels of fast-
ing blood glucose. Body mass index (BMI) and waist 
circumference (WC) were calculated in each patient. 
Diagnosis of obesity was made in patients with BMI 
≥30 kg/m2. AH was defined as values of ≥140 mmHg 
systolic blood pressure and/or ≥90 mmHg diastolic 
blood pressure, or in cases of documented history of 
AH when the blood pressure values  were normal if 
case the patient was undergoing an antihypertensive 
treatment (8). The diagnostic criteria for DM used in 
this study were: a FPG level of 126 mg/dL (7.0 mmol/
L) or higher, or a 2-hour plasma glucose level of 200 
mg/dL (11.1 mmol/L) or higher during a 75 g OGTT, or 
a random plasma glucose of 200 mg/dL (11.1 mmol/
L), or glycated hemoglobin A1C ≥6.5% (9). MS was di-
agnosed by the presence of more than three of the 
criteria of the International Diabetes Federation (10), 
i.e. abdominal obesity diagnosed by WC of >94 cm in 
men and >80 cm in women, plus two of the following 
criteria: 1) elevated triglycerides ≥150 mg/dl or spe-
cific treatment for this lipid abnormality, 2) reduced 
HDL-C <40 mg/dl in men and <50 mg/dl in women 
or specific treatment for this lipid abnormality, 3) ele-
vated blood pressure >130/85 mmHg or treatment of 
previously diagnosed hypertension, and 4) elevated 
FPG >100 mg/dL or previously diagnosed type 2 DM. 
Patients classified as smokers were current smokers 
who smoked a minimum of 15 cigarettes per day 
for more than 5 years. The 10-year Framingham risk 
score (FRS) for general cardiovascular disease, which 
includes age, gender, TC, HDL-C, systolic blood pres-
sure, smoking status, and DM, was applied to patients 
of both groups. FRS was classified as low (<10% risk), 
intermediate (10-20% risk) or high risk (>20% risk) 
(11).
The data were recorded in a database using Mi-
crosoft XL and subsequently underwent a descriptive 
statistical analysis; the test used was the chi-square 
test. The student’s t-test was used to evaluate the dif-
ferences between groups. The estimated relative risk 
was calculated using parameter odds ratio (OR). Sig-
nificance threshold was P<0.05.
ReSultS
The severity of chronic plaque psoriasis was mild 
(mean PASI 8.63±5.43) in 32 patients (22.54%) and 
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moderate to severe (mean PASI 17.28±11.86) in 110 
patients (77.46%). History of psoriasis ranged from 6 
months to 38 years, with a mean of 9.62±6.02 years.
The prevalence rates of cardiovascular risk fac-
tors in patients with mild psoriasis, moderate to se-
vere psoriasis, and in controls are presented in Table 
1. We found a significant higher prevalence of MS in 
the patient group, at 13.4% (12.5% and 14.54% in pa-
tients with mild and moderate-to-severe psoriasis, 
respectively) compared to controls 10.77% (OR=1.3; 
95% CI: 0.64-2.54, P=0.032). Individual components 
of MS such as WC, elevated triglycerides, reduced 
HDL-C, impaired FPG, and AH were also more preva-
lent in cases than in controls (Table 1). We observed a 
higher prevalence of obesity in patients with psoria-
sis (28.87%) compared to controls (23.35%) (OR=1.33; 
95% CI: 0.79-2.22; P=0.016). The prevalence of DM, 
AH, and smoking was also significantly higher among 
patients with psoriasis than in controls (OR=1.18, 95% 
CI: 0.43-3.25, P=0.047; OR=1.18; 95% CI: 0.75-1.86, 
P=0.032 and OR=1.5; 95% CI: 0.86-2.56, P=0.006, for 
DM, AH and smoking, respectively).
The mean values of triglycerides, TC, LDL-C, and 
HDL-C in the patients with mild, moderate to severe 
psoriasis, and the control group are shown in Table 
2. Plasma triglyceride levels in patients with psoria-
sis were significantly raised compared with those of 
the controls (163.21±56.72 and 109.47±45.29 mg/dL, 
respectively) (P<0.001). Serum TC levels were signifi-
cantly increased in the patient group (223.42±142.72 
mg/dL) when compared to controls (204.3±82.51 
mg/dL) (P<0.01). LDL-C levels in the patient group 
were 118.62±36.79 mg/dL and 104.26±31.86 mg/
dL in controls, this difference being statistically sig-
nificant (P<0.05). HDL-C levels among patients with 
psoriasis were lower compared with those of the con-
trols (44.63±11.39 mg/dL and 52.46±8.65 mg/dL, in 
patients and controls, respectively) (P<0.01).
The 10-years FRS was significantly higher in pa-
tients with psoriasis than in controls (8.36±5.75 vs. 
6.61±4.13; P<0.001) (Table 1). FRS was higher in 
men (Figure 1) and in patients older than 50 years 
(Figure 2). According to the severity of psoriasis, FRS 
increased significantly from mild to moderate-to-se-
table 1. Characteristics of study population
Characteristics of study population Psoriasisn=142
Controls
n=167 P value 














Metabolic syndrome 19 (13.4%) 18 (10.77%) 0.032
Waist circumference (>94 cm in men and >80 cm 
in women)
55 (38.73%) 61 (36.52%) 0.045
Obesity (BMI≥30 kg/m2) 41 (28.87%) 39 (23.35%) 0.016
Arterial hypertension (>140/90 mm Hg) 61 (42.3%) 65 (38.9%) 0.032
Triglycerides ( ≥150 mg/dl) 37 (26.05%) 38 (22.75%) 0.034
Total cholesterol (≥200 mg/dl) 40 (28.17%) 40 (23.95%) 0.026
LDL cholesterol (>100 mg/dl) 43 (30.28%) 42 (25.15%) 0.019
HDL cholesterol( <40 mg/dl in men and <50 mg/dl 
in women)
27 (19.01%) 31 (18.56%) 0.052
Diabetes mellitus 8 (5.63%) 8 (4.8%) 0.047


















*P value <0.05 was considered statistically significant
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vere psoriasis (6.82±4.48 to 8.8±6.71; P=0.003). There 
was no correlation between duration of psoriasis and 
cardiovascular risk score (OR 1.02, 95% CI: 0.005-0.34; 
P=0.617). Because of the young age of our popula-
tions, the majority of patients had a low cardiovascu-
lar risk (78.87% and 83.23% for the patients group and 
controls, respectively; P<0.001). However, a higher 
proportion of patients with psoriasis compared with 
controls had intermediate and high cardiovascular 
risk levels (11.97% and 9.15% for the patient group, 
9.58% and 7.18% for controls, P<0.001) (Table 1).
dISCuSSIon
An increasing number of epidemiological studies 
continues to demonstrate that cardiovascular diseas-
es and their associated risk factors are more common 
in patients with psoriasis than in the general popu-
lation (2,12-15). The association between psoriasis 
and cardiometabolic comorbidities may arise from 
a genetic predisposition, but may also be the conse-
quence of specific lifestyles including smoking, alco-
hol consumption, and sedentary habits (16). Biologi-
cal mechanisms involved in cardiovascular diseases 
in patients with psoriasis are still largely unknown 
but their action seems to be multifactorial (6). Recent 
advances in understanding of the immunopathogen-
esis and genetics of psoriasis have changed the focus 
from treating it as a single organ disease confined 
to skin structures to approaching it as a systemic in-
flammatory condition (17,18). Systemic inflammation 
has also been shown to be an independent cardio-
vascular risk factor (19). Systemic inflammation and 
hypercoagulability predispose to atherothrombosis 
and seem to be important features of MS (20-22). One 
hypothetical mechanism linking psoriasis, MS, and 
cardiovascular disease centers on chronic Th 1 and 
Th 17 inflammation (23,24). Pro-inflammatory cyto-
kines such as TNF-α, interleukin-1, and interleukin-6 
seem to play a central role (21,25,26). TNF-α induces 
oxidative stress, which exacerbates pathological pro-
cesses leading to oxidized LDL-C and dyslipidemia, 
glucose intolerance, insulin resistance, AH, endothe-
lial dysfunction, and atherogenesis (27,28). Currently, 
elevated homocysteine levels are also considered an 
independent risk factor for cardiovascular disease, 
cerebrovascular disease, and peripheral vascular dis-
ease (29,30). Whereas patients with psoriasis seem 
Figure 1. 10-years Framingham Risk Score according 
to severity of psoriasis and gender
Figure 2. 10-years Framingham Risk Score according 
to severity of psoriasis and age













Triglycerides (mg/dl) 111.78±39.87 169.72±56.47 163.21±56.72 109.47±45.29 <0.001
Total cholesterol (mg/dl) 217.87±38.2 224.69±79.87 223.42±142.72 204.3±82.51 <0.01
LDL-Cholesterol (mg/dl) 104.13±28.92 119.85±34.52 118.62±36.79 104.26±31.86 <0.05
HDL-Cholesterol (mg/dl) 49.8±7.18 44.12±9.16 44.63±11.39 52.46±8.65 <0.01
*P value <0.05 was considered statistically significant
Irimie et al. Acta Dermatovenerol Croat
Cardiovascular risk factors in patients with psoriasis    2015;23(1):28-35
32 ACTA DERMATOVENEROLOGICA CROATICA
to have higher homocysteine levels, hyperhomo-
cysteinemia may be considered another aspect that 
contributes to the increased risk of cardiovascular 
disease (31,32).
Lifestyle factors such as smoking, alcohol con-
sumption, sedentary lifestyle, and systemic psoria-
sis therapy may influence cardiovascular risk factors 
and may have a negative direct impact on these risk 
factors (33). Patients with psoriasis have a decreased 
quality of life and increased rates of depression so 
they tend to smoke and drink more than the gen-
eral population as well as eat excessively, leading 
to obesity (34,35). Dyslipidemia is one of the major 
traditional risk factors for cardiovascular disease. The 
abnormalities in the lipid profile seen in psoriasis 
patients, in addition to promoting atherosclerosis, 
might also lead and maintain the inflammatory reac-
tion in the skin (36). It is still controversial whether 
changes in lipid profile are primary or secondary to 
psoriasis or perhaps due to medications such as reti-
noids, cyclosporine, and methotrexate (37,38), while 
other medications used for psoriasis as TNF α inhibi-
tors have been found to decrease the risk of cardio-
vascular disease by reducing the inflammation (39). 
Thus, in our study we evaluated the lipid profile as a 
predictor of cardiovascular diseases in patients with 
psoriasis (without treatment) and we found more 
prevalent lipid abnormalities in patients with psoria-
sis compared with the control group. Overall, various 
studies reported serum TC, HDL-C, and LDL-C levels 
of psoriatic patient as high, low, or normal (2,40,41), 
thus these lipid profile abnormalities might be genet-
ically determined rather than acquired (42). However, 
dietary and socioeconomic factors may also explain 
their high frequency. 
The prevalence of MS in general population is 
estimated between 15% and 24% (43). Psoriasis pa-
tients have an increased prevalence of MS that ranges 
between 14% and 40%, in some studies being almost 
double compared to that of the control population 
(44, 45). Our study revealed an overall prevalence of 
13.4% of the MS in patients with psoriasis, prevalence 
that was correlated with psoriasis severity. Psoriasis 
is a multigenic disease and predisposition to MS in 
psoriasis may have a genetic component (46). Several 
genetic studies showed a significant association be-
tween psoriasis and CDKAL1 gene implicated also in 
DM (47). 
Azfar et al. (48) found psoriasis as an independent 
risk factor for type 2 DM, the risk being greatest in 
patients with severe disease. The appearance of DM 
in psoriasis patient depends on duration of psoriasis 
and the severity of the systemic inflammation (49). 
Overproduction of Th 1 cytokines in psoriasis seems 
to increase insulin resistance (15). Another factor that 
may interfere with the development of diabetes in 
psoriasis is the use of topical corticosteroids for long 
periods.
A significant association between obesity and 
psoriasis was noted. Compared with control popula-
tion, the psoriasis patients in our study had a signifi-
cant higher prevalence of obesity. The relationship 
between psoriasis and obesity is thought to be bidi-
rectional with psoriasis increasing the risk of obesity 
and obesity predisposing patients to psoriasis (50).
Psoriasis has been found to be an independent as-
sociated with AH (15). The mechanisms of relationship 
between psoriasis and AH are not clear established. 
Elevated plasma renin activity, elevated angiotensin-
converting enzyme activity, and elevated endothelin-
1 in patients with psoriasis could contribute to poor 
blood pressure control (51, 52).
Cardiovascular events occur more frequently in 
patients with severe psoriasis and long disease du-
ration (41). Considering the importance of associa-
tion of cardiovascular events with psoriasis severity, 
we assessed cardiovascular risk factors in patients 
with mild and moderate to severe psoriasis. In the 
group with mild psoriasis the assessed parameters 
had mean values  close to those of the control group, 
whereas in patients with moderate to severe psoriasis 
the frequency of cardiovascular risk factors increased 
compared with the control group. FRS is a validated 
tool to predict the absolute risk of cardiovascular 
events at 10 years in adults by stratifying patients into 
3 risk categories: low (<10% risk), intermediate (10% 
to 20%), and high (>20%) (11). We found that FRS is 
significant higher in patients with chronic plaque 
psoriasis than in age and gender matched controls. 
The risk was higher in patients older than 50 years, in 
men compared to women, and in patients with mod-
erate to severe psoriasis. Armstrong et al. (53) found 
that mild psoriasis is associated with a significantly 
increased risk of myocardial infarction (RR 1.29; 95% 
CI: 1.02-1.63) and stroke (RR 1.12; 95% CI: 1.08-1.16), 
and severe psoriasis was associated with a signifi-
cantly increased risk of myocardial infarction (RR 1.70; 
95% CI: 1.32-2.18), stroke (RR 1.56; 95% CI: 1.32-1.84), 
and cardiovascular mortality (RR 1.39; 95% CI: 1.11-
1.74). Mehta et al. (54) considers that severe psoriasis 
to confer an additional 6.2% attributable risk on a 10-
year incidence of major adverse cardiac events. Pso-
riasis was also found to be an independent risk factor 
for mortality (OR 1.86; 95% CI: 1.56-2.21) (55).
The limitations of our study are that it was a de-
scriptive study in which disease and exposure were 
Irimie et al. Acta Dermatovenerol Croat
Cardiovascular risk factors in patients with psoriasis    2015;23(1):28-35
33ACTA DERMATOVENEROLOGICA CROATICA
measured simultaneously in our study population, 
and the group of patients with psoriasis represented, 
in a high proportion, patients with moderate to se-
vere disease who attend our hospital in Brasov (Ro-
mania).
ConCluSIon
Psoriasis, especially moderate to severe psoriasis, 
seems to represent a risk factor for cardiovascular dis-
eases. This could be due to an increased prevalence 
of traditional cardiovascular risk factors in people 
with psoriasis, the effect of chronic inflammation in 
patients with psoriasis, or a combination of both fac-
tors. Patients with psoriasis should be risk-assessed 
for cardiovascular diseases, and comorbidities should 
be actively managed.
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